Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors

International Journal of Cancer

Volumn 113, Issue 4, 2005, Pages 611-618

  Cabrera, Carmen M ^a   López Nevot, Miguel Ángel ^a   Jiménez, Pilar ^a   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Colorectal tumors; HLA allelic loss; HLA B44; Tapasin; Tumor tissue

Indexed keywords

ASPARTIC ACID; CHAPERONE; HLA B44 ANTIGEN; TAPASIN;

ALLELE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BLADDER TUMOR; COLORECTAL TUMOR; CONTROLLED STUDY; CRYOPRESERVATION; GENE MUTATION; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MICRODISSECTION; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SURFACE PROPERTY;

ANTIPORTERS; COLORECTAL NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; HLA-B ANTIGENS; HUMANS; IMMUNOGLOBULINS; LARYNGEAL NEOPLASMS; LOSS OF HETEROZYGOSITY; MEMBRANE TRANSPORT PROTEINS; MOLECULAR CHAPERONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 11144278264     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20526     Document Type: Article

References (49)

1. Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncol 1997;8:111-41.
2. Singal DP, Ye M, Ni J, Snider DP. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett 1996;50:149-54.
3. Garcia-Lora A, Martínez MS, Algarra I, Gaforio JJ, Garrido F. MHC class I deficient metastatic tumor variants immunoselected by T lymphocytes are originated by coordinated downregulation of APM components. Int J Cancer 2003;106:521-7.
4. Benitez R, Godelaine D, López-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998;52:520-9.
5. Jiménez P, Cantón J, Collado A, Cabrera T, Serrano A, Real LM, García A, Ruiz-Cabello F, Garrido F. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999;83:91-7.
6. Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome 6p21 region. Cancer Immunol Immunother 2002;51:389-96.
7. 2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003;61:211-9.
8. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res 1998;58:2149-57.
9. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 1993;90:2842-5.
10. Koopman LA, van der Slik AR, Giphart MJ, Fleuren GJ. Human leukocyte antigen class I gene mutations in cervical cancer. J Nat Cancer Inst 1999;91:1669-77.
11. Jiménez P, Cabrera T, Mendez R, Esparza C, Cozar JM, Tallada M, López-Nevot MA, Ruiz-Cabello F, Garrido F. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics 2001;53:606-10.
12. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
13. Cabrera T, Maleno I, López-Nevot MA, Redondo M, Fernández MA, Garrido A, Garrido F. High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol 2003;64:941-50.
14. Imanishi T, Akaza T, Kimura A, Tokunga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuko K, eds. HLA 1991. New York: Oxford University Press, 1992. 1065-166.
15. Fleischhauer K, Kernan NA, Dupont B, Yang SY. The two major subtypes of HLA-B44 differ for a single amino acid in codon 156. Tissue Antigens 1991;31:133-7.
16. Bodmer JG, Marsh SGE, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Hansen JA, Mach B, Mayr WR, Parham P, Petersdorf EW, et al. Nomenclature for factors of the HLA system, 1998. Tissue Antigens 1999;53:407-46.
17. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition of class I histocompatibility antigens. Nature 1987;329:512-8.
18. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol 1991;219:277-319.
19. Keever CA, Leong N, Cunningham I, Copelan EA, Avalos BR, Klein J, Kapoor N, Adams PW, Orosz CG, Tutschka PJ. HLA-B44 directed cytotoxic T cell associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 1994;14:137-45.
20. Fleischhauer K, Kernan NA, O'Reilly RJ, Dupont B, Yang SY. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 1990;323:1818-22.
21. Petersdorf EW, Setoda T, Smith AG, Hansen JA. Analysis of HLA-B44 alleles encoded on extended HLA haplotypes by direct automated sequencing. Tissue Antigens 1994;44:211-6.
22. Mattiuz PL, Di Paolo E, Fossombroni V, Menicucci A, Pradella F, Porfirio B, Rombola G. HLA-B44 subtypes and the chance of finding HLA compatible donor/recipient pairs for bone marrow transplantation: a haplotype study of 303 Italian families. Tissue Antigens 1997;50:602-9.
23. Santos S, Vicario JL, Merino JL, Balas A. HLA-B44 subtyping in a Spanish population: further evidence of Caucasian population diversity. Tissue Antigens 1997;49:124-8.
24. Grandea AG III, Golovina TN, Hamilton SE, Siriram V, Spies T, Brutkiewicz RR, Harty JT, Eisenlohr LC, Van Kaer L. Impaired assembly yet normal trafficking of MHC class I molecules in tapasin mutant mice. Immunity 2000;13:213-22.
25. Park B, Lee S, Kim E, Ahn K. A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence. J Immunol 2003;170:961-8.
26. Cabrera T, Collado A, Fernández MA, Ferrón A, Sancho J, Ruiz-Cabello F, Garrido F. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998;52:114-23.
27. Garrido F, Cabrera T, Accola RS, Bensa JC, Wodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Charron D., eds. HLA and cancer. In: HLA, genetic diversity of HLA: functional and medical implications, vol. 1. EDK, 1997. 445-52.
28. Domena JD, Little AM, Madrigal AJ, Hildebrand WH, Johnston-Dow L, Du Toit E, Bias WB, Parham P. Structural Heterogeneity in HLA-B70, a high frequency antigen of black populations. Tissue Antigens 1993;42:509-17.
29. Curran MD, Williams F, Earle JAP, Rima BK, Van Dam MG, Bunce M, Middleton D. Long-range PCR amplification as an alternative strategy for characterizing novel HLA-B alleles. Eur J Immunogenet 1996;23:297-309.
30. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Storkel S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transpoter-associated with antigen-processing down-regulation. Clin Cancer Res 2003;9:1721-7.
31. Lutz CT, Smith KD, Greazel NS, Mace BE, Jensen DA, McCutcheon JA, Goeken NE. Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. J Immunol 1994;153:4099-110.
32. Purcell AW, Gorman JJ, Garcia-Peydró M, Paradela A, Burrows SR, Talbo GH, Laham N, Peh CA, Reynolds EC, López de Castro JA, McCluskey J. Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J Immunol 2001;166:1016-27.
33. Macdonald W, Williams DS, Clements CS, Gorman JJ, Kjer-Nielsen L, Brooks AG, McCluskey J, Rossjohn J, Purcell AW. Identification of a dominant self-ligand bound to three HLA-B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex. FEBS Lett 2002;527:27-32.
34. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosemberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
35. Johnsen A, France J, Sy MS, Harding CV. Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 1998;58:3660-7.
36. Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today 1998;19:539-42.
37. Cresswell P, Bangia N, Dick T, Diedrich G. The nature of the MHC class 1 peptide loading complex. Immunol Rev 1999;172:21-8.
38. Sadasivan B, Lehener PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996;5:103-14.
39. Solheim JC, Harris MR, Kindle CS, Hansen TH. Prominence of β2-microglobulin, class I heavy chain conformation and tapasin in the interactions of class I heavy chain with calreticulin and the transported associated with antigen processing. J Immunol 1997;158:2236-41.
40. Lehner PJ, Surman MJ, Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line 220. Immunity 1998;8:221-31.
41. Bangia N, Lehner PJ, Hughes EA, Surman M, Creswell P. The N-terminal region of tapasin is required to stabilize the MHC class I loading complex. Eur J Immunol 1999;29:1858-70.
42. Li S, Paulsson KM, Chen S, Sjogren HO, Wang P. Tapasin is required for efficient peptide binding to transporter associated with antigen processing. J Biol Chem 2000;275:1581-6.
43. Barnden MJ, Purcell AW, Gorman JJ, McCluskey J. Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J Immunol 2000;165:322-30.
44. Peh CA, Burrows SR, Barnden M, Khanna R, Cresswell P, Moss DJ, McCluskey J. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I. Immunity 1998;8:531-42.
45. Purcell AW, Kelly AJ, Peh CA, Dudek NL, McCluskey J. Endogenous and exogenous factors contributing to the surface expression of HLA B27 on mutant antigen presenting cells. Hum Immunol 2000;61:120-30.
46. Yu YY, Myers NB, Hilbert CM, Harris MR, Balendiran GK, Hansen TH. Definition and transfer of a serological epitope for peptide-empty forms of MHC class I. Int Immunol 1999;11:1897-906.
47. Yu YY, Turnquist HR, Myers NB, Balendiran GK, Hansen TH, Solheim JC. An extensive region of an MHC class I α2 domain loop influences interaction with the assembly complex. J Immunol 1999;163:4427-33.
48. Seliger B, Schreiber K, Delp K, Meissner M, Hammers S, Reichert T, Pawlischko K, Tampe R, Huber CH. Downregulation of the constitutive tapasin expression in human tumors cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 2000;57:39-45.
49. Garbi N, Tiwari N, Momburg F, Hammerling GJ. A major role for tapasin as a stabilizer of the TAP peptide transporter and consequences for MHC class I expression. Eur J Immunol 2003;33:264-73.